Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darapladib in Dyslipidemic Patients
NCT00734032Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2008
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of darapladib in atherosclerosis (4 arms), sponsored by GSK. Primary endpoint: Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 Activity. Started Aug 2008; status: completed.
02
Drugs
darapladib
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT00734032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00734032.